. intolerance). Ibrutinib is The present gold standard therapy for patients with relapsed/refractory condition, determined by the results of numerous period I-III trials, 115–119 but this is also switching for 2 main good reasons: (i) an increasing proportion of individuals presently obtain ibrutinib as frontline therapy; and (ii) a couple of sig